Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNH2 | Q12809 | 14/20 | 0.63 |
| ▸ | CACNA1I | Q9P0X4 | 10/20 | 0.63 |
| ▸ | CACNA1H | O95180 | 2/20 | 0.48 |
| ▸ | CACNA1G | O43497 | 1/20 | 0.48 |
| ▸ | GSK3B | P49841 | 1/20 | 0.48 |
| ▸ | HTR4 | Q13639 | 2/20 | 0.48 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4277544 | 0.94 | KCNH2 (0.70) | KCNH2CACNA1ICACNA1HGSK3BHTR4 | |
| SCHEMBL14770043 | 0.91 | KCNH2 (0.53) | KCNH2CACNA1ICACNA1HCACNA1GGSK3B | |
| SCHEMBL16471376 | 0.91 | KCNH2 (0.63) | KCNH2CACNA1ICACNA1HCACNA1GCYP2D6 | |
| SCHEMBL4284138 | 0.90 | KCNH2 (0.60) | KCNH2CACNA1ICACNA1HCACNA1GCYP2D6 | |
| SCHEMBL4276555 | 0.90 | KCNH2 (0.60) | KCNH2CACNA1ICACNA1HCACNA1GHTR4 | |
| SCHEMBL14769944 | 0.90 | KCNH2 (0.62) | KCNH2CACNA1ICACNA1HGSK3BHTR4 | |
| SCHEMBL14770038 | 0.90 | CACNA1I (0.62) | KCNH2CACNA1ICACNA1HCACNA1GGSK3B | |
| SCHEMBL4274996 | 0.90 | KCNH2 (0.59) | KCNH2CACNA1ICACNA1HCACNA1GCYP2D6 | |
| SCHEMBL14769967 | 0.89 | KCNH2 (0.59) | KCNH2CACNA1ICACNA1HCACNA1GHTR4 | |
| SCHEMBL4273171 | 0.89 | KCNH2 (0.58) | KCNH2CACNA1ICACNA1HCACNA1GCYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160175315-A1 | N-PIPERIDINYL ACETAMIDE DERIVATIVES AS CALCIUM CHANNEL BLOCKERS | NEUROMED PHARMACEUTICALS, LTD. (CA) | 2016-06-23 | — | — | US | disclosed |
| US-9096522-B2 | N-piperidinyl acetamide derivatives as calcium channel blockers | Zalicus Pharmaceuticals, Ltd. (CA) | 2015-08-04 | — | — | US | disclosed |
| US-20140011996-A1 | N-PIPERIDINYL ACETAMIDE DERIVATIVES AS CALCIUM CHANNEL BLOCKERS | ZALICUS PHARMACEUTICALS LTD. (CA) | 2014-01-09 | — | — | US | disclosed |
| US-20140011996-A1 | N-PIPERIDINYL ACETAMIDE DERIVATIVES AS CALCIUM CHANNEL BLOCKERS | ZALICUS PHARMACEUTICALS LTD. (CA) | 2014-01-09 | — | — | US | disclosed |
| US-8569344-B2 | N-piperidinyl acetamide derivatives as calcium channel blockers | ZALICUS PHARMACEUTICALS LTD. (CA) | 2013-10-29 | — | — | US | disclosed |
| US-20130065926-A1 | N-PIPERIDINYL ACETAMIDE DERIVATIVES AS CALCIUM CHANNEL BLOCKERS | MARK G. DEGIACOMO, CHAPTER 7 TRUSTEE OF EPIRUS BIOPHARMACEUTICALS, INC. | 2013-03-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130065926-A1 | N-PIPERIDINYL ACETAMIDE DERIVATIVES AS CALCIUM CHANNEL BLOCKERS | CACNA1G, CACNA1H, CACNA1B | KCNH2 60/4885CACNA1I 4/4885CACNA1H 2/4885 |
| US-20140011996-A1 | N-PIPERIDINYL ACETAMIDE DERIVATIVES AS CALCIUM CHANNEL BLOCKERS | CACNA1G, CACNA1H, CACNA1B | KCNH2 60/4885CACNA1I 4/4885CACNA1H 2/4885 |
| US-20160175315-A1 | N-PIPERIDINYL ACETAMIDE DERIVATIVES AS CALCIUM CHANNEL BLOCKERS | CACNA1G, CACNA1H, CACNA1B | KCNH2 60/4885CACNA1I 4/4885CACNA1H 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.